Watson Pharmaceuticals, Inc.
Records under this name other than the patents Watson Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.
Back to Watson Pharmaceuticals, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,959,946 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 8,084,058 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Term ended Term ended Aug 26, 2026 · From the USPTO record | Term ended | Term ended Aug 26, 2026 | From the USPTO record |
| US 7,785,627 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Jul 31, 2026 · From the USPTO record | Term ended | Term ended Jul 31, 2026 | From the USPTO record |
| US 9,060,941 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Mar 11, 2025 · Low confidence | Term ended | Ended no later than Mar 11, 2025 | Low confidence |
| US 7,303,763 | Compositions for conjugated estrogens and associated methods Formerly held Term ended Term ended Apr 6, 2024 · From the USPTO record | Term ended | Term ended Apr 6, 2024 | From the USPTO record |
| US 8,470,368 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Nov 1, 2023 · From the USPTO record | Term ended | Term ended Nov 1, 2023 | From the USPTO record |
| US 8,309,125 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Sep 19, 2023 · From the USPTO record | Term ended | Ended no later than Sep 19, 2023 | From the USPTO record |
| US 8,668,931 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Sep 19, 2023 · From the USPTO record | Term ended | Ended no later than Sep 19, 2023 | From the USPTO record |
| US 8,551,516 | Administration of non-oral androgenic steroids to women Formerly held Term ended Term ended Aug 31, 2022 · From the USPTO record | Term ended | Term ended Aug 31, 2022 | From the USPTO record |
| US 6,630,166 | Compositions for conjugated estrogens and associated methods Formerly held Term ended Term ended Feb 12, 2022 · From the USPTO record | Term ended | Term ended Feb 12, 2022 | From the USPTO record |